Skip to main content
logo
Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
3.310
+0.070 (2.16%)
At close: Oct 15, 2026

Neuphoria Therapeutics Financials Overview

Millions USD. Fiscal year is Jul - Jun.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Revenue
1.171.1715.65--4.17
Revenue Growth
-92.50%-92.50%---499.60%
Gross Profit
1.171.1715.65---6.85
Operating Income
-9.01-9.01-0.83-17.8-21.56-12.12
Net Income
-13.45-13.45-0.37-15.49-21.38-14.99
Earnings Per Share
-3.06-3.06-0.23-18.62-0.01-0.01
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Cash & Investments
19.8719.8714.2112.6112.123.13
Total Debt
0.030.030.150.270.350.48
Net Cash (Debt)
19.8319.8314.0612.3411.7522.65
Net Cash Growth
41.03%41.03%13.99%4.99%-48.12%9.32%
Net Cash Per Share
4.514.518.6614.820.010.02

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Operating Cash Flow
-12.35-12.350.08-14.68-14.64-14.99
Capital Expenditures
------0
Free Cash Flow
-12.35-12.350.08-14.68-14.64-14.99
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Gross Margin
100.00%100.00%100.00%---164.21%
Operating Margin
-767.32%-767.32%-5.30%---290.62%
Pretax Margin
-1157.51%-1157.51%-5.35%---362.51%
Profit Margin
-1145.66%-1145.66%-2.36%---359.34%
FCF Margin
-1052.07%-1052.07%0.49%---359.30%

Valuation
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingOct '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
P/FCF Ratio
--172.83---
PS Ratio
15.2520.110.85---